Jean‐Frédéric Blanc

Université de Bordeaux — France

Medicine · Health Sciences

65h-index19.0kcitations342works15.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(134), Pancreatic and Hepatic Oncology Research(78), Liver Disease Diagnosis and Treatment(62), Cholangiocarcinoma and Gallbladder Cancer Studies(53), Cancer Genomics and Diagnostics(34)

Publications334 total

Real-world efficacy of nanoliposomal irinotecan in patients with advanced pancreatic cancer
BMC Cancer·2025Open Access
Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional Study
Liver Cancer·2025Open Access
530 CD40 agonist mitazalimab + mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma: dose characterization based on exposure response and biomarker analysis from the OPTIMIZE-1 study
Regular and Young Investigator Award Abstracts·2025Open Access
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1
Cell Reports Medicine·2025· 1 citedOpen Access
3128eP Predictive value of PD-L1 expression in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial
Annals of Oncology·2025
55P Proteomic profiling of advanced hepatocellular carcinoma identifies predictive signatures of response to treatments
ESMO Open·2025Open Access
1499P Interim analysis of the REFINE-IO study of systemic therapies in patients (pts) with unresectable hepatocellular carcinoma (uHCC) following first-line (1L) immune checkpoint inhibitor (ICI) combination therapy
Annals of Oncology·2025
A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data
Digestive and Liver Disease·2025· 2 cited
186P Safety and response to neoadjuvant lenvatinib for poor-prognosis BCLC A hepatocellular carcinoma treated by percutaneous ablation in a curative intent: Preliminary analysis of the French LENVABLA multicentre phase II trial (NCT05113186)
Annals of Oncology·2025Open Access
153P Evolution of second-line practices in the era of immunotherapy: Real-life data from the French prospective CHIEF cohort
Annals of Oncology·2025Open Access
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study
The Oncologist·2025· 1 citedOpen Access
Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer.
Journal of Clinical Oncology·2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
The Lancet·2025· 148 citedOpen Access
LBP-029-YI Spatial transcriptomics of the tumor microenvironment discriminates inflamed tumors responsive or resistant to atezolizumab + bevacizumab in patients with advanced HCC
Journal of Hepatology·2025Open Access
Abstract 1893: Proteomic profiling of advanced hepatocellular carcinoma identifies predictive signatures of response to treatments
Cancer Research·2025
Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers
European Journal of Cancer·2025· 5 cited
Real-World Efficacy of Radioembolization With or Without Chemotherapy in Patients with Locally Advanced Intrahepatic Cholangiocarcinoma
Journal of Cancer Science and Clinical Therapeutics·2025Open Access
Metallic trace elements in pancreatic tissue are associated with higher risk of pancreatic adenocarcinoma - METAPANDA study
Pancreatology·2025Open Access
A0109 – Impact of neoadjuvant chemo-immunotherapy on surgical outcomes of radical cystectomy in the AURA trial (Oncodistinct-004)
European Urology·2025
Alpha-1 antitrypsin deficiency and primary liver cancers
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer·2025· 4 citedOpen Access
page 1 of 17Next →

Frequent Co-authors

Jessica Zucman‐Rossi(16), Paulette Bioulac‐Sage(15), Philippe Mathurin(13), Pierre Nahon(13), Albert Tran(13), Dominique Guyader(12), Dominique Larrey(12), Victor de Lédinghen(12), Denis Ouzan(12), Fabien Zoulim(12), Dominique Roulot(12), Paul Calès(12), Laurent Alric(12), Marc Bourlière(12), Armand Abergel(12), Ariane Mallat(12), Jean‐Didier Grangé(12), Yannick Bacq(12), Christophe Pilette(12), Christine Silvain(12)